ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Kadmon Holdings, Inc. Investors with Losses to Secure Counsel Before Important Deadline KDMN

By Globe Newswire10 days ago

NEW YORK, May 04, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Kadmon Holdings, Inc. (NASDAQ:KDMN) between October 1, 2020 and March 10, 2021, inclusive (the Class Period) of the important June 2, 2021 lead plaintiff deadline.

SO WHAT: If you purchased Kadmon securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

AD

WHAT TO DO NEXT: To join the Kadmon class action, go to or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than June 2, 2021. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience or resources. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) the New Drug Application for belumosudil for the treatment of chronic graft-versus-host disease (cGVHD) (the Belumosudil NDA) with the U.S. Food and Drug Administration (FDA) was incomplete and/or deficient; (2) the additional new data that Kadmon submitted in support of the Belumosudil NDA in response to an information request from the FDA materially altered the Belumosudil NDA submission; (3) accordingly, the initial Belumosudil NDA submission lacked the degree of support that the Company had led investors to believe; (4) accordingly, the FDA was likely to extend the Prescription Drug User Fee Act (PDUFA) target action date to review the Belumosudil NDA; and (5) as a result, defendants' public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

Continue read on benzinga.com